Literature DB >> 20063295

Dyslipidemia in the elderly: should it be treated?

Madhan Shanmugasundaram1, Steven J Rough, Joseph S Alpert.   

Abstract

Elderly or older adults constitute a rapidly growing segment of the United States population, thus resulting in an increase in morbidity and mortality related to cardiovascular disease-an increase that is reaching epidemic proportions. Dyslipidemia is a well established risk factor for cardiovascular disease and is estimated to account for more than half of the global cases of coronary artery disease. Despite the increased prevalence of dyslipidemia in the older adult population, controversy persists regarding the benefits of treatment in this group. Epidemiologic studies have shown that dyslipidemia is often underdiagnosed and under treated in this population probably as a result of a paucity of evidence regarding the impact of treatment in delaying the progression of atherosclerotic disease, concerns involving increased likelihood of adverse events or drug interactions, or doubts regarding the cost effectiveness of lipid-lowering therapy in older adults. In conclusion, despite the proven efficacy of lipid-lowering therapy in decreasing cardiovascular morbidity and mortality, these therapies have been underutilized in older patients. Copyright 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063295      PMCID: PMC6653208          DOI: 10.1002/clc.20702

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  41 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

3.  Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Authors:  D Hunt; P Young; J Simes; W Hague; S Mann; D Owensby; G Lane; A Tonkin
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

4.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

Authors:  Kenneth Rockwood; Susan Kirkland; David B Hogan; Chris MacKnight; Heather Merry; René Verreault; Christina Wolfson; Ian McDowell
Journal:  Arch Neurol       Date:  2002-02

5.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study.

Authors:  Rozenn N Lemaitre; Bruce M Psaty; Susan R Heckbert; Richard A Kronmal; Anne B Newman; Gregory L Burke
Journal:  Arch Intern Med       Date:  2002-06-24

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  11 in total

1.  Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study.

Authors:  Sophie Lochner; Wilhelm Kirch; Christoph Schindler
Journal:  Eur J Clin Pharmacol       Date:  2011-12-30       Impact factor: 2.953

2.  Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.

Authors:  Huaichao Luo; Xueping Zhang; Ping Shuai; Yuanying Miao; Zimeng Ye; Ying Lin
Journal:  J Genet       Date:  2017-12       Impact factor: 1.166

Review 3.  Drug Therapy of Dyslipidemia in the Elderly.

Authors:  Srikanth Yandrapalli; Shashvat Gupta; Gabriela Andries; Howard A Cooper; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

4.  Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study.

Authors:  Michelle C Odden; Michael G Shlipak; Heather E Whitson; Ronit Katz; Patricia M Kearney; Chris defilippi; Shani Shastri; Mark J Sarnak; David S Siscovick; Mary Cushman; Bruce M Psaty; Anne B Newman
Journal:  Atherosclerosis       Date:  2014-09-30       Impact factor: 5.162

5.  Free triiodothyronine in relation to coronary severity at different ages: Gensini score assessment in 4206 euthyroid patients.

Authors:  Bing-Yang Zhou; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Ying Gao; Ping Qing; Xiao-Lin Li; Yao Wang; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  J Geriatr Cardiol       Date:  2016-12       Impact factor: 3.327

6.  Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs.

Authors:  Esther Muya; Appolinary Kamuhabwa
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

7.  Examining the Influence of Early Life Stress on Serum Lipid Profiles and Cognitive Functioning in Depressed Patients.

Authors:  Ágnes Péterfalvi; Nándor Németh; Róbert Herczeg; Tamás Tényi; Attila Miseta; Boldizsár Czéh; Maria Simon
Journal:  Front Psychol       Date:  2019-08-06

8.  Which diagnostic criteria of metabolic syndrome are predictors of cardiovascular diseases in elderly populations?

Authors:  Arinrada Ladla; Pramote Tongkrajai; Sompong Srisaenpang; Penprapa Siviroj; Surakrant Yutthakasemsunt; Somsak Tiamkao; Verajit Chotmongkol; Kittisak Sawanyawisuth
Journal:  J Clin Transl Endocrinol       Date:  2020-12-31

9.  PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders.

Authors:  Bogna Grygiel-Górniak; Iwona Ziółkowska-Suchanek; Elżbieta Kaczmarek; Maria Mosor; Jerzy Nowak; Mariusz Puszczewicz
Journal:  Clin Interv Aging       Date:  2018-03-22       Impact factor: 4.458

10.  Benefits and barriers: a qualitative study on online social participation among widowed older adults in Southwest China.

Authors:  Yan Hong; Jingjing Fu; Dehui Kong; Siqi Liu; Zhu Zhong; Jing Tan; Yu Luo
Journal:  BMC Geriatr       Date:  2021-08-03       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.